GERN Stock Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.80 |
| 52 Week High | US$4.30 |
| 52 Week Low | US$1.64 |
| Beta | 0.55 |
| 1 Month Change | 10.47% |
| 3 Month Change | 80.09% |
| 1 Year Change | 22.58% |
| 3 Year Change | 165.73% |
| 5 Year Change | 150.00% |
| Change since IPO | -50.97% |
Recent News & Updates
Recent updates
Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03
Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
Mar 15Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Mar 05Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25Is Geron (NASDAQ:GERN) Using Debt Sensibly?
May 12An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued
Dec 20Geron: A Major Catalyst For Shareholders Arrives In January - At Last
Sep 16Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?
Sep 14Geron rises on narrower-than-expected Q2 loss
Aug 12Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt
Aug 05Geron: Waiting For Godot
Jul 15Geron: TLR Is 10 Months Away
May 03Is Geron (NASDAQ:GERN) Using Too Much Debt?
Feb 25Geron: Just One More Year Of Patience, Then Decision Time
Feb 23Shareholder Returns
| GERN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.3% | 0.5% | 2.7% |
| 1Y | 22.6% | 3.4% | 26.0% |
Return vs Industry: GERN exceeded the US Biotechs industry which returned 3.4% over the past year.
Return vs Market: GERN underperformed the US Market which returned 26% over the past year.
Price Volatility
| GERN volatility | |
|---|---|
| GERN Average Weekly Movement | 28.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GERN's share price has been volatile over the past 3 months.
Volatility Over Time: GERN's weekly volatility has increased from 16% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 141 | Chip Scarlett | www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| GERN fundamental statistics | |
|---|---|
| Market cap | US$2.30b |
| Earnings (TTM) | -US$201.39m |
| Revenue (TTM) | US$520.00k |
4,334x
P/S Ratio-11.2x
P/E RatioIs GERN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GERN income statement (TTM) | |
|---|---|
| Revenue | US$520.00k |
| Cost of Revenue | US$125.89m |
| Gross Profit | -US$125.37m |
| Other Expenses | US$76.02m |
| Earnings | -US$201.39m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | -24,110.38% |
| Net Profit Margin | -38,729.81% |
| Debt/Equity Ratio | 24.0% |
How did GERN perform over the long term?
See historical performance and comparison